nach oben

Drugs

Erschienen in:

01.12.2011 | Leading Article

Serotonergic Anti-Obesity Agents

Past Experience and Future Prospects

verfasst von: Dr Jason C. G. Halford, Emma J. Boyland, Clare L. Lawton, John E. Blundell, Joanne A. Harrold

Erschienen in: Drugs | Ausgabe 17/2011

Einloggen, um Zugang zu erhalten

Abstract

The role of serotonin (5-hydroxytryptamine) in appetite control is long established. Serotonergic manipulations reduce food intake in rodents in a manner consistent with satiety. In humans, drugs such as fenfluramine, dexfenfluramine and sibutramine all reduce energy intake, suppress hunger and enhance satiety. Effects on eating behaviour and subjective sensations of appetite are associated with the weight loss-inducing effects of these treatments. Currently, no appetite-suppressing drugs are approved specifically for the treatment of obesity. However, a new generation of serotonergic drugs have progressed through clinical development. The serotonin 5-HT_2C− receptor selective agonist lorcaserin, a drug specifically developed to target satiety without producing the side effect profiles of its predecessors, has been shown to significantly reduce energy intake and body weight. The weight loss produced by lorcaserin appears modest, and behavioural effects, particularly its supposed satiety-enhancing effects, have yet to be characterized. The monoaminergic re-uptake inhibitor tesofensine has also been shown to produce impressive weight loss in smaller-scale clinical studies. It remains unclear if this drug produces any effects on appetite mediated by serotonin, or whether weight loss is produced largely through enhanced energy expenditure. Evidence indicates that tesofensine strengthens satiety, but behavioural specificity and psychological side effects remain an issue. The serotonergic system remains a viable target for anti-obesity treatment. In this review, we examine the limited behavioural data available on these two new CNS-acting appetite suppressants.

National Institute for Health and Clinical Excellence. Obesity: the prevention, identification, assessment and management of overweight and obesity in adults and children. London: NICE, 2006 Dec [online]. Available from URL: http://guidance.nice.org.uk/CG43 URL [Accessed 2011 Oct 14]

Hall KD, Sack G, Chandramohan D, et al. Quantification of the effect of energy imbalance on body weight. Lancet 2011; 378: 836–7CrossRef

Pasman WJ, Saris WH, Westerterp-Plantenga MS. Predictors of weight maintenance. Obes Res 2006; 7: 43–50

Keys A, Brozek J, Henschel A, et al. The biology of human starvation. Vol. 1 & 2. St. Paul (MN): University of Minnesota Press, 1950

Blundell JE, Levin F, King NA, et al. Over-consumption and obesity: peptides and susceptibility to weight gain. Regul Pept 2008; 149: 32–8PubMedCrossRef

Gautier JF, Chen KW, Salbe D, et al. Differential brain responses to satiation in obese and lean men. Diabetes 2000; 49: 838–46PubMedCrossRef

Geliebter A, Yahav EK, Gluck ME, et al. Gastric capacity, test meal intake, and appetitive hormones in binge eating disorder. Physiol Behav 2004; 81: 735–40PubMedCrossRef

Meyer JE, Pudel V. Experimental studies on food-intake in obese and normal weight subjects. J Psychosom Res 1972; 16: 305–8PubMedCrossRef

Spiegel TA, Wadden TA, Foster GD. Objective measurement of eating rate during behavioral treatment of obesity. Behav Ther 1991; 22: 61–7CrossRef

10.

Barkeling B, Ekman S, Rössner S. Eating behaviour in obese and normal weight 11-year-old children. Int J Obes 1992; 16: 335–60

11.

Laessle RG, Lehrke S, Dückers S. Laboratory eating behavior in obesity. Appetite 2007; 49: 399–404PubMedCrossRef

12.

Otsuka R, Tamakoshi K, Yatsuya H, et al. Eating fast leads to obesity: findings based on self-administered questionnaires among middle-aged Japanese men and women. J Epidemiol 2006; 16: 117–24PubMedCrossRef

13.

Maruyama K, Sato S, Ohira T, et al. The joint impact on being overweight of self reported behaviours of eating quickly and eating until full: cross sectional survey. BMJ 2008; 337: a2002PubMedCrossRef

14.

Llewellyn CH, van Jaarsveld CH, Boniface D, et al. Eating rate is a heritable phenotype related to weight in children. Am J Clin Nutr 2008; 88: 1560–6PubMedCrossRef

15.

Mars M, de Graaf C, de Groot CP, et al. Fasting leptin and appetite responses induced by a 4-day 65%-energy-restricted diet. Int J Obes 2006; 30: 122–8CrossRef

16.

Warren C, Cooper PJ. Psychological effects of dieting. Br J Clin Psychol 1988; 27: 269–70PubMedCrossRef

17.

Polivy J. Psychological consequences of food restriction. J Am Diet Assoc 1996; 96(6): 589–92PubMedCrossRef

18.

Hill AJ. The psychology of food craving. Proc Nutr Soc 2007; 66: 277–85PubMedCrossRef

19.

Karlsson J, Persson LO, Sjöström L, et al. Psychometric properties and factor structure of the three-factor eating questionnaire (TFEQ) in obese men and women, results from the Swedish obese subjects (SOS) study. Int J Obes 2000; 24: 1715–25CrossRef

20.

Barkeling B, King NA, Näslund E, et al. Characterization of obese individuals who claim to detect no relationship between their eating pattern and sensations of hunger or fullness. Int J Obes 2007; 31: 435–9CrossRef

21.

Provencher V, Drapeau V, Tremblay A, et al. Eating behaviours and indexes of body composition in men and women from the Quebéc family study. Obes Res 2003; 11: 783–92PubMedCrossRef

22.

Dykes J, Brunner EJ, Martikeainene PT, et al. Socio-economic gradient in body size and oboist among women: the role of dietary restraint, disinhibition and hunger in the Whitehall II study. Int J Obes 2004; 28: 262–8

23.

Lawson OJ, Williamson DA, Champagne CM, et al. The association of body weight, dietary intake, and energy expenditure with dietary restraint and disinhibition. Obes Res 1995; 3: 153–61PubMed

24.

Williamson DA, Lawson OJ, Brookes ER, et al. Association of body mass with dietary restraint and disinhibition. Appetite 1995; 25: 31–41PubMedCrossRef

25.

Hays NP, Bathalon CP, McCrory MA, et al. Eating behaviour correlates of adult weight gain and obesity in healthy women aged 55–65 y. Am J Clin Nutr 2002; 75: 476–48PubMed

26.

Bellisle F, Clement K, La Barzic M, et al. The eating inventory and body adiposity from leanness to massive obesity: a study of 2509 adults. Obes Res 2004; 12: 2023–30PubMedCrossRef

27.

Borg P, Fogelholm M, Kukkonen-Harjula K. Food selection and eating behaviour during weight maintenance intervention and 2-y follow-up in obese men. Int J Obes 2004; 28: 1548–54CrossRef

28.

Stunkard A, Kaplan D. Eating in public places: a review of reports of the direct observation of eating behavior. Int J Obes 1977; 1: 89–101PubMed

29.

Blundell JE, Stubbs RJ, Golding C, et al. Resistance and susceptibility to weight gain: individual variability in response to a high fat diet. Physiol Behav 2005; 86: 614–22PubMedCrossRef

30.

Halford JCG, Harrold JA, Boyland EJ, et al. Serotonergic drugs: effects on appetite expression and use for the treatment of obesity. Drugs 2007; 67(1): 27–55PubMedCrossRef

31.

Heisler LK, Cowley MA, Tecott LH, et al. Activation of central melanocortin pathways by fenfluramine. Science 2002; 297: 609–11PubMedCrossRef

32.

Heisler LK, Cowley MA, Kishi T, et al. Central serotonin and melanocortin pathways regulating energy homeostasis. Ann N Y Acad Sci 2003; 994: 169–74PubMedCrossRef

33.

Heisler LK, Jobst EE, Sutton GM, et al. Serotonin reciprocally regulates melanocortin neurons to modulate food intake. Neuron 2006; 51: 239–49PubMedCrossRef

34.

Halford JCG, Blundell JE. Separate systems for serotonin and leptin in appetite control. Ann Med 2000; 32: 222–32PubMedCrossRef

35.

Blundell JE. Is there a role for serotonin (5-hydroxytryptamine) in feeding? Int J Obes 1977; 1(1): 15–42PubMed

36.

Blundell JE, Latham CJ. Pharmacological manipulation of feeding behaviour: possible influences of serotonin and dopamine on food intake. In: Garattini S, Samanin R, editors. Central mechanisms of anorectic drugs. New York: Raven Press, 1978: 83–109

37.

Blundell JE, Latham CJ. Characteristic adjustments to the structure of feeding behaviour following pharmacological treatments: effects of amphetamine and fenfluramine and the antagonism by pimozide and metergoline. Pharmacol Biochem Behav 1980; 12: 717–22PubMedCrossRef

38.

Halford JCG, Wanninayake SCD, Blundell JE. Behavioural satiety sequence (BSS) for the diagnosis of drug action on food intake. Pharmacol Biochem Behav 1998; 61: 159–68PubMedCrossRef

39.

Clifton PG, Barnfield AMC, Philcox L. A behavioural profile of fluoxetine-induced anorexia. Psychopharmacology (Berl) 1989; 97(1): 89–95CrossRef

40.

Simansky KJ, Viadya AH. Behavioural mechanisms for the anorectic actions of the serotonin (5-HT) uptake inhibitor sertraline in rats: comparison with directly acting agonists. Brain Res Bull 1990; 25: 953–60PubMedCrossRef

41.

Halford JCG, Blundell JE. 5-Hydroxytryptaminergic drugs compared on the behavioural sequence associated with satiety [abstract]. Br J Pharmacol 1993; 100: 95

42.

Kitchener SJ, Dourish CT. An examination of the behavioural specificity of hypophagia induced by 5-HT1B, 5-HT1C and 5-HT2 receptor agonists using the post-prandial sequence in rats. Psychopharmacology (Berl) 1994; 113(3-4): 368–77CrossRef

43.

Halford JCG, Blundell JE. Metergoline antagonizes fluoxetine induced suppression of food intake but not changes in the behavioural satiety sequence. Pharmacol Biochem Behav 1996; 54: 745–51PubMedCrossRef

44.

Halford JCG, Blundell JE. The 5-HT 1B receptor agonist CP-94,253 reduces food intake and preserves the behavioural satiety sequence. Physiol Behav 1996; 60: 933–9PubMed

45.

Lee MD, Simansky KJ. CP-94,253: a selective serotonin1B (5-HT1B) agonist that promotes satiety. Psychopharmacology (Berl) 1997; 131(3): 264–70CrossRef

46.

Lee MD, Kennett GA, Dourish CT, et al. 5-HT1B receptors modulate components of satiety in the rat: behavioural and pharmacological analyses of the selective serotonin1B agonist CP-94,253. Psychopharmacology (Berl) 2002; 164(1): 49–60CrossRef

47.

Hewitt KN, Lee MD, Dourish CT, et al. Serotonin 2C receptor agonists and the behavioural satiety sequence in mice. Pharmacol Biochem Behav 2002; 71: 691–700PubMedCrossRef

48.

Kennett GA, Curzon G. Evidence that the hypophagia induced by mCPP and TFMPP requires 5-HT1C and 5-HT1B receptors; hypophagia induced by RU-24969 only requires 5-HT1B receptors. Psychopharmacology (Berl) 1988; 96: 93–100CrossRef

49.

Kennett GA, Curzon G. Evidence that mCPP may have behavioural effects mediated by central 5-HT1C receptors. Br J Pharmacol 1988; 94: 137–47PubMedCrossRef

50.

Kennett GA, Curzon G. Potencies of antagonists indicate that 5-HT1C receptors mediate 1–3(chlorophenyl)-piperazine-induced hypophagia. Br J Pharmacol 1991; 10: 2016–20CrossRef

51.

Jackson HC, Bearham MC, Hutchins LJ, et al. Investigation of the mechanisms underlying the hypophagic effects of the 5-HT and noradrenaline reuptake inhibitor, sibutramine, in the rat. Br J Pharmacol 1997; 121: 1613–8PubMedCrossRef

52.

Vickers SP, Dourish CT, Kennett GA. Evidence that hypophagia induced by d-fenfluramine and d-norfenfluramine in the rat is mediated by 5-HT2C receptors. Neuropharmacology 2001; 41: 200–9PubMedCrossRef

53.

Higgs S, Cooper AJ, Barnes NM. Reversal of sibutramine-induced anorexia with a selective 5-HT2C receptor antagonist. Psychopharmacology (Berl) 2011; 214(4): 941–7CrossRef

54.

Tecott LH, Sun LM, Akanna SF, et al. Eating disorder and epilepsy in mice lacking 5-HT2C serotonin receptors. Nature 1995; 374: 542–6PubMedCrossRef

55.

Nonogaki K, Abdullah L, Goulding EH, et al. Hyperactivity and reduced energy cost of physical activity in serotonin 5-HT2C receptor mutant mice. Diabetes 2003; 52: 315–20PubMedCrossRef

56.

Bouwknecht JA, van der Guten J, Hijsenm TH, et al. Male and female 5-HT1B receptor knockout mice have higher body weights than wild types. Physiol Behav 2001; 74: 507–16PubMedCrossRef

57.

Rogers PJ, Blundell JE. Effect of anorexic drugs on food intake and the micro-structure of eating in human subjects. Psychopharmacology (Berl) 1979; 66(2): 159–65CrossRef

58.

Goodall E, Silverstone T. Differential effect of dfenfluramine and metergoline on food intake in human subjects. Appetite 1988; 11: 215–88PubMedCrossRef

59.

McGuirk J, Silverstone T. The effect of 5-HT re-uptake inhibitor fluoxetine on food intake and body weight in healthy male subjects. Int J Obes 1990; 14: 361–72PubMed

60.

Hansen DL, Toubro S, Stock MJ, et al. Thermogenic effects of sibutramine in humans. Am J Clin Nutr 1998; 68: 1180–6PubMed

61.

Chapelot D, Mamonier C, Thomas F, et al. Modalities of the food intake-reducing effect of sibutramine in humans. Physiol Behav 2000; 68: 299–308PubMedCrossRef

62.

Blundell JE, Hill AJ. Sensitivity of the appetite control system in obese subjects to nutritional and serotoninergic challenges. Int J Obes 1990; 14: 219–33PubMed

63.

Drent ML, Zelissen PMJ, Kopperchaar HPF, et al. The effect of dexfenfluramine on eating habits in a Dutch ambulatory android overweight population with an over-consumption of snacks. Int J Obes 1995; 19: 299–304

64.

Lawton CL, Wales JK, Hill AJ, et al. Serotoninergic manipulation, meal-induced satiety and eating patterns. Obes Res 1995; 3: 345–56PubMed

65.

Pijl H, Koppeschaar HPF, Willekens FLA, et al. Effect of serotonin re-uptake inhibition by fluoxetine on body weight and spontaneous food choice in obesity. Int J Obes 1991; 15: 237–42PubMed

66.

Rolls BJ, Shide DJ, Thorward ML, et al. Sibutramine reduces food intake in non-dieting women with obesity. Obes Res 1998; 6: 1–11PubMed

67.

Halford JCG, Boyland EJ, Cooper SJ, et al. The effects of sibutramine on the microstructure of eating behaviour and energy expenditure in obese women. J Psychopharmacol 2010; 24: 99–109PubMedCrossRef

68.

Walsh AE, Smith KA, Oldman AD. M-Chlorophenylpiperazine decreases food intake in a test meal. Psychopharmacol 1994; 116: 120–2CrossRef

69.

Cowen PJ, Sargent PA, Williams C, et al. Hypophagic, endocrine and subjective responses to m-chlorophenylpiperazine in healthy men and women. Hum Psychopharmacol 1995; 10: 385–91CrossRef

70.

Sargent PA, Sharpley AL, Williams C, et al. 5-HT2C receptor activation decreases appetite and body weight in obese subjects. Psychopharmacol 1997; 133: 309–12CrossRef

71.

Haddock CK, Poston WSC, Dill PL, et al. Pharmacotherapy for obesity: a quantitative analysis of four decades of published randomized clinical trials. Int J Obes 2002; 26: 262–73CrossRef

72.

Arterburn DE, Crane PK, Veenstra DL. The efficacy and safety of sibutramine for weight loss: a systematic review. Arch Int Med 2004; 164: 994–1003CrossRef

73.

Padwal R, Li SK, Lau DCW. Long-term pharmacotherapy for overweight and obesity: a systematic review and meta-analysis of randomized controlled trials. Int J Obes 2003; 27: 1437–46CrossRef

74.

Abeniam L, Moride Y, Brenot F, et al. Appetite suppressant drugs and the risk of primary pulmonary hypertension. N Engl J Med 1996; 335: 609–16CrossRef

75.

James WPT, Caterson ID, Coutinho W, et al. Effects of sibutramine on cardiovascular outcomes in overweight and obesity subjects. N Engl J Med 2010; 363: 905–17PubMedCrossRef

76.

Astrup A. Drug management of obesity: efficacy versus safety. N Engl J Med 2010; 363: 288–90PubMedCrossRef

77.

Smith SR, Prosser WA, Donahue DF, et al. Lorcaserin (APD356), a selective 5-HT2C agonist, reducing body weight in obese men and women. Obes 2009; 17: 494–500CrossRef

78.

Bjenning C, Williams J, Whelan K, et al. Chronic oral administration of APD356 significantly reduces body weight and fat mass in obesity-prone (DIO) male and female rats [abstract]. Int J Obes 2004; 28 (1 Suppl.): 214s

79.

Smith S, Anderson J, Frank A, et al. The effects of APD356, a selective 5-HT2C agonist, on weight loss in a 4 week study in healthy obese patients [abstract]. Obes Res 2005; 13 Suppl.: 101–ORCrossRef

80.

Martin CK, Redman LM, Zhang J, et al. Lorcaserin, a 5-HT2C receptor agonist, reduced body weight by decreasing energy intake within influencing energy expenditure. J Clin Endocrinol Metab 2011; 96: 837–45PubMedCrossRef

81.

Smith SR, Wiessman NJ, Anderson CM, et al. Multicenter, placebo-controlled trial for lorcaserin for weight management. N Engl J Med 2010; 363: 245–56PubMedCrossRef

82.

Halford JCG. Obesity: lorcaserin — not a new weapon in the battle with appetite. Nat Rev Endocrinol 2010; 6: 663–4PubMedCrossRef

83.

Doggrell SA. Tesofensine: a novel potent weight loss medicine. Exp Opin Investig Drugs 2009; 18: 1043–6CrossRef

84.

Bello NT, Zahner MR. Tesofensine, amonoanime reuptake inhibitor for the treatment of obesity. Curr Opin Investig Drugs 2009; 10: 1105–16PubMed

85.

Lehr T, Staab A, Tillmann C, et al. Contribution of the active metabolite M1 to the pharmacological activity of tesofensine in vivo: a pharmacokinetic-pharmacodynamic modelling approach. Br J Pharmacol 2008; 153: 164–74PubMedCrossRef

86.

Berridge KC. The debate over dopamine’s role in reward: the case for incentive salience. Psychopharmacol 2007; 191: 391–431CrossRef

87.

Axel AMD, Mikkelsen JD, Hansen HH. Tesofensine, a novel triple monoamine reuptake inhibitor, induces appetite suppression by indirect stimulation of alpha 1 adrenoceptor and dopamine D1 receptor pathways in the diet-induced obese rat. Neuropsychopharmacology 2010; 35(7): 1464–76PubMedCrossRef

88.

Hansen HH, Hansen G, Tang-Christensen M, et al. The novel triple monoamine reuptake inhibitor tesofensine induced sustained weight loss and improved glycaemic control in the diet-induced obese rat: comparison to sibutramine and rimonabant. Eur J Pharmacol 2010; 636: 88–95PubMedCrossRef

89.

Sjödin A, Gasteyger C, Nielen A-LH, et al. The effect of the tripe monoamine reuptake inhibitor tesofensine on energy metabolism and appetite in overweight and moderately obese mean. Int J Obesity 2010; 34: 1634–43CrossRef

90.

Astrup A, Madshad S, Breum L, et al. Effect of tesofensine on body weight loss, body composition and quality of life in obese patients: a randomised, double-blind, placebo-controlled trial. Lancet 2008; 372: 1906–13PubMedCrossRef

91.

Schoedel KA, Meier D, Chekroborty B. Subjective and objective effects of the novel triple reuptake inhibitor tesofensine in recreational stimulant users. Clin Pharmacol Ther 2010; 88(1): 69–78PubMedCrossRef

Titel: Serotonergic Anti-Obesity Agents
Past Experience and Future Prospects
verfasst von: Dr Jason C. G. Halford
Emma J. Boyland
Clare L. Lawton
John E. Blundell
Joanne A. Harrold
Publikationsdatum: 01.12.2011
Verlag: Springer International Publishing
Erschienen in: Drugs / Ausgabe 17/2011
Print ISSN: 0012-6667
Elektronische ISSN: 1179-1950
DOI: https://doi.org/10.2165/11596680-000000000-00000

Springer Medizin

Abstract

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 17/2011

Current Status of Targeted Therapies for Mantle Cell Lymphoma

Adjuvant Therapy for Early Colon Cancer

Pharmacological Considerations for the Proper Clinical Use of Aminoglycosides

Eculizumab

Single-Pill Telmisartan and Amlodipine

Liraglutide